PET TUMOR AND PROLIFERATION IMAGING VIA CATIONIC AMINO ACID TRANSPORT

Summary

Principal Investigator: JONATHAN EDWARD MCCONATHY
Abstract: DESCRIPTION (provided by applicant): The purpose of this K08 Mentored Clinical Scientist Research Career Development Award application is to provide additional critical mentored training and research experience to achieve my goal of becoming an independent investigator focused on molecular imaging for oncology. My training to date during my Ph.D. and research track radiology residency has focused on the design, synthesis and preliminary preclinical evaluation of PET tracers for brain monoamine transporters and 18F-labeled amino acids (AAs) for tumor imaging. Completion of the training and research plan in this proposal will provide additional key experiences in tumor biology, animal tumor models, kinetic analysis of PET tracers, and translational and clinical research using advanced magnetic resonance imaging (MRI) in conjunction with PET tracers. This additional training will provide me with the critical knowledge base and skill set needed to independently design and pursue translational research projects in cancer imaging. The research plan in this proposal focuses on developing novel 18F-triazole AAs synthesized via click the click reaction for in vivo PET imaging of cationic AA transport, tumor proliferation and response to radiation therapy. Cationic AA transport and metabolism play critical roles in tumor biology including cell proliferation through polyamine metabolism and in angiogenesis through nitric oxide synthesis. However, there are no 18F- labeled compounds available for imaging cationic AA transport. To address this unmet need in oncologic molecular imaging, we will perform the following Specific Aims: 1) Synthesize and characterize novel 18F-labeled 1,2,3-triazole substituted AAs optimized for cationic AA transport. 2) Validate the lead 18F-triazole AAs as in vivo imaging probes for cationic AA transport. 3) Measure in vivo tumor proliferation using the lead 18F-triazole AA in the mouse 66 breast cancer model and the human-in-mouse (HIM) breast cancer model. 4) Differentiate viable tumor from radiation-induced changes with the lead 18F-triazole AA in mice with intracranial DBT gliomas. Novel 18F-labeled triazole AAs will be synthesized, and their mechanisms of transport will be determined in vitro using rat 9L gliosarcoma, mouse DBT glioma and mouse mammary adenocarcinoma 66 cell lines. Biodistribution and microPET studies will be performed in rodents implanted with these tumors using the 18F- triazole AAs that are the best substrates for cationic AA transport. The in vivo uptake of these AAs in tumors will be correlated with mRNA and protein levels of cationic AA transporters. The in vivo uptake and kinetics of the lead 18F-triazole AA will also be correlated with in vivo tumor cell proliferation as measured with BrDU incorporation by mouse 66 tumors and human-derived breast tumors with and without functional p53 in the HIM model. The ability of the lead 18F-triazole AA to distinguish residual viable tumor from post-treatment effects including radiation necrosis will be assessed in mice with intracranial DBT tumors. The training and career development plan in this proposal includes didactic course work in tumor biology and clinical trial design. I will also have visiting rotations at the University of Washington in Seattle to gain additional experience with PET tumor proliferation imaging with [18F]FLT and at the J|lich Research Center in Germany to learn more about the clinical applications of PET-MRI using radiolabeled amino acids. I will also be actively involved in multimodality translational oncologic imaging through studies in human subjects with PET tracers as well as advanced MRI through the Center for Clinical Imaging Research (CCIR). My Mentor, Dr. Robert H. Mach, will provide expertise in radiotracer design, synthesis and tumor proliferation imaging, and my Co-Mentor Dr. Keith M. Rich will provide expertise in preclinical and clinical neuro-oncology and animal models of gliomas. I also will have an advisory committee who will meet semi-annually to provide guidance for my research and career development activities. The research environment at Washington University in St. Louis approaches the ideal for me, with outstanding faculty and resources in radiochemistry, basic, translational and clinical oncologic, and imaging research and clinical trials. My overall goal is to use the experience from the training component of this grant in conjunction with the data obtained through the research plan to successfully secure independent grant support including R01 funding to conduct human studies with these new PET tracers. We expect this research to provide novel PET tracers for imaging cationic AA transport, proliferation and response to radiation therapy with direct relevance to clinical oncology. Near the end of the award period, I will submit an application to the Clinical Trials Methodology Workshop sponsored by the Radiological Society of North America as well as a R21 or R01 grant application based on the tracers developed through the research component of this proposal. Completion of the research and training plan would position me to become an independent investigator at the conclusion of the award period.
Funding Period: 2011-09-01 - 2016-08-31
more information: NIH RePORT

Top Publications

  1. pmc Radiosynthesis and biological evaluation of alpha-[F-18]fluoromethyl phenylalanine for brain tumor imaging
    Chaofeng Huang
    Department of Radiology, Washington University School of Medicine, Campus Box 8223, St Louis, MO 63110, USA
    Nucl Med Biol 40:498-506. 2013
  2. pmc 18F-AFETP, 18F-FET, and 18F-FDG imaging of mouse DBT gliomas
    Kiran Kumar Solingapuram Sai
    Department of Radiology, Washington University School of Medicine, St Louis, Missouri, USA
    J Nucl Med 54:1120-6. 2013
  3. pmc Imaging the L-type amino acid transporter-1 (LAT1) with Zr-89 immunoPET
    Oluwatayo F Ikotun
    Department of Radiology, Washington University School of Medicine, St Louis, Missouri, United States of America
    PLoS ONE 8:e77476. 2013

Research Grants

Detail Information

Publications3

  1. pmc Radiosynthesis and biological evaluation of alpha-[F-18]fluoromethyl phenylalanine for brain tumor imaging
    Chaofeng Huang
    Department of Radiology, Washington University School of Medicine, Campus Box 8223, St Louis, MO 63110, USA
    Nucl Med Biol 40:498-506. 2013
    ..The tumor imaging properties of both enantiomers of this new tracer were evaluated through cell uptake, biodistribution and microPET studies in the mouse DBT model of high grade glioma...
  2. pmc 18F-AFETP, 18F-FET, and 18F-FDG imaging of mouse DBT gliomas
    Kiran Kumar Solingapuram Sai
    Department of Radiology, Washington University School of Medicine, St Louis, Missouri, USA
    J Nucl Med 54:1120-6. 2013
    ..The tracer (18)F-AFETP is a structural analog of histidine and is a lead compound for imaging cationic amino acid transport, a relatively unexplored target for oncologic imaging...
  3. pmc Imaging the L-type amino acid transporter-1 (LAT1) with Zr-89 immunoPET
    Oluwatayo F Ikotun
    Department of Radiology, Washington University School of Medicine, St Louis, Missouri, United States of America
    PLoS ONE 8:e77476. 2013
    ..These results are the first report of direct PET imaging of LAT1 and demonstrate the potential of immunoPET agents for imaging specific amino acid transporters. ..

Research Grants30

  1. Characterization of Pathways Controlling Cancer at the Level of Gene Regulation
    Phillip A Sharp; Fiscal Year: 2013
    ..The interactions and involvement of Rb and miRNAs in induction of cell death following DNA damage will also be studied. ..
  2. SPORE in Soft Tissue Sarcoma
    Samuel Singer; Fiscal Year: 2013
    ..abstract_text> ..